Phase 1 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be at least 18 years old (or at least 15 years old if you are in the US and have a germ cell tumor)
- Your tumor must test positive for a protein called CLDN6
- You must have been diagnosed (confirmed by lab testing of tissue or cells) with advanced, returned, or spread cancer of the ovaries, fallopian tubes, peritoneum, uterus/endometrium, or a germ cell tumor that has stopped responding to previous treatment
- You must be well enough to carry out daily activities at an acceptable level, as measured by a standard medical scale (confirm with trial site)
- Your doctors expect you to live for at least 3 more months
- Your liver, kidneys, and bone marrow must be functioning well enough to meet the trial's requirements
Who may not be able to join:
- If you have cancer that has spread to the brain, you may still be considered — but only if those brain tumors have been treated and are shown to be stable on scans
- You must not have an active autoimmune disease (a condition where your immune system attacks your own body)
- You must not have needed regular steroid medications (such as prednisone) or other medicines that suppress your immune system within the 14 days before starting the trial
- You must not have a significant heart, lung, or digestive system condition that could affect your participation (confirm with trial site)
- You must not currently have an active hepatitis B or hepatitis C infection
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of adverse events; Incidence of dose-limiting toxicities (DLTs); Incidence of cytokine release syndrome (CRS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.